THE SAFETY STORY:

See the results of 6-week placebo-controlled studies1

About NUPLAZID

In the 6-week studies, 80% of patients were aged 65 years or older1

80% of patients were aged 65 years or older

In the 6-week studies, no differences in safety were reported based on age, gender, or MMSE score

  • 27% had mild cognitive impairment (MMSE 21-24)

  • The maximum age in the clinical studies was 90 years2

MMSE=Mini-Mental State Examination.

Safety profile demonstrated in placebo-controlled studies1

Results demonstrated in placebo-controlled studies

*Based on 6-week placebo-controlled studies.

A demonstrated safety profile in elderly patients with Parkinson’s disease (PD) psychosis1

In the 6-week placebo-controlled trials:

zero

 
 

  • No events of neuroleptic malignant syndrome, tardive dyskinesia, or serotonin syndrome were reported with NUPLAZID® (pimavanserin) 34 mg 2,3

eight-percent
  • 8% (n=202) of patients treated with NUPLAZID 34 mg discontinued due to adverse reactions vs 4% (n=231) with placebo1

    • The adverse reactions that occurred in more than one patient and with an incidence of at least twice that of placebo were hallucination (2% NUPLAZID vs <1% placebo), urinary tract infection (1% NUPLAZID vs <1% placebo), and fatigue (1% NUPLAZID vs 0% placebo)

check up

 
 

  • Fewer cases of orthostatic hypotension were reported for NUPLAZID 34 mg compared with placebo (1.0% vs 5.2%)2

sedation related
  • Treatment with NUPLAZID 34 mg was associated with a lower incidence of sedation-related events (6.4%) compared with placebo (5.2%)2

    • Somnolence has been identified during postapproval use of NUPLAZID and has been added to the prescribing information1

For healthcare professionals